Oncoinvent Grants Options to New Medical Director
Oncoinvent granted options to its new medical director.
Related stories
Boston Scientific Reports Q3 Sales of $5.138 Billion, Lowers 2026 EPS Guidance
Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, and adjusted EPS of $0.73. It lowered full-year adjusted EPS guidance to $3.16–$3.18, citing Chi
M impact | EQUITY | Oct 30, 2026, 02:02 AM UTC
Indonesia's Benchmark Stock Index Falls 0.9% to 5,054.729
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Welspun Corp Q2 Net Profit Rises 3%, Plans Rs 2,280 Crore Expansion
Welspun Corp reported a 3% rise in Q2 net profit. Revenue from operations was Rs 4,644 crore. It cleared investments of up to Rs 2,280 crore across the US and Jordan; US capacity i
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Milky Mist Q2 Net Profit Nearly Triples as Revenue Tops ₹1,000 Crore
Milky Mist Dairy Food reported Q2 FY27 revenue from operations of ₹1,089.4 crore, up 41.6% year on year. The supplied report says net profit nearly tripled.
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Brigade Group Q2 Profit Rises 29% to Rs 219 Crore
Real estate sales were Rs 1,827 crore. EBITDA climbed, and project launches reached 2.4 million sq ft during the September quarter. Profit before tax rose to Rs 288 crore in Q2 FY2
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC
Blue Star Q2 Net Profit Rises 25% to Rs 124 Crore
Blue Star's consolidated revenue grew to Rs 2,931 crore in the September quarter of FY27. EBITDA rose more slowly amid pressure on operating margins.
M impact | EQUITY | Oct 30, 2026, 02:01 AM UTC